Chiesi Farmaceutici S.p.A.

Quick facts

Marketed products

• Atimos® · Respiratory / Pulmonology
  Atimos is a tiotropium bromide inhalation powder that acts as a long-acting anticholinergic (muscarinic antagonist) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.
• Beclometasone/Formoterol · Respiratory/Pulmonology
  Beclometasone is a corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle, together providing anti-inflammatory and bronchodilatory effects.
• CHF1535 · Respiratory/Pulmonology
  CHF1535 is a fixed-dose combination of beclomethasone dipropionate and formoterol fumarate that reduces airway inflammation and provides bronchodilation for respiratory disease management.
• CHF5993 · Other
• elapegademase-lvlr
• Formoterol Inhalation Solution · Respiratory
  Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
• Foster · Other
• Foster BDP/Formoterol · Respiratory
  Foster combines beclomethasone dipropionate (a corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD.
• Glycopyrrolate + Formoterol · Respiratory / Pulmonology
  Glycopyrrolate is an anticholinergic agent that blocks muscarinic receptors to reduce airway secretions and bronchoconstriction, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle.
• Elfabrio · Metabolic
  Elfabrio works by reducing the accumulation of a specific lipid in the body.
• Poractant alfa (Curosurf®) · Respiratory/Neonatology
  Poractant alfa is a natural pulmonary surfactant that reduces surface tension in the lungs and restores normal respiratory function in neonates with respiratory distress syndrome.
• umeclidinium bromide and vilanterol trifenatate · Respiratory / Pulmonology
  Umeclidinium is a long-acting muscarinic antagonist and vilanterol is a long-acting beta-2 agonist that together relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.

Phase 3 pipeline

• BDP DPI 2 months · Respiratory / Pulmonology
  BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.
• BDP/FF/GB · Respiratory/Pulmonology
  BDP/FF/GB is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways.
• BDP/FF + Tiotropium · Respiratory
  BDP/FF (beclomethasone/formoterol) is an inhaled corticosteroid plus long-acting beta-2 agonist combination that reduces airway inflammation and bronchospasm, while tiotropium is a long-acting muscarinic antagonist that provides sustained bronchodilation.
• BDP/Formoterol Next DPI · Respiratory/Pulmonology
  BDP/Formoterol combines an inhaled corticosteroid (beclomethasone dipropionate) with a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation.
• BDP HFA 100 µg pMDI · Respiratory / Pulmonology
  BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.
• BDP/salbutamol CFC pMDI · Respiratory/Pulmonology
  BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.
• BDP/salbutamol HFA pMDI · Respiratory / Pulmonology
  BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.
• Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium · Respiratory/Pulmonology
  This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways.
• Beclometasone/Formoterol/Glycopyrrolate · Respiratory/Pulmonology
  This triple-combination inhaler delivers a corticosteroid (beclometasone) to reduce airway inflammation, a long-acting beta-2 agonist (formoterol) to dilate airways, and an anticholinergic (glycopyrrolate) to further relax airway smooth muscle.
• Beclomethasone (BDP) · Respiratory / Pulmonology
  Beclomethasone is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs.
• Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium · Respiratory/Pulmonology
  This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways.
• Beclomethasone dipropionate/Salbutamol combination · Respiratory/Pulmonology
  This combination inhaler delivers a corticosteroid to reduce airway inflammation and a short-acting beta-2 agonist to rapidly relax bronchial smooth muscle.
• Beclomethasone plus formoterol fixed combination · Respiratory/Pulmonology
  Beclomethasone (a corticosteroid) reduces airway inflammation while formoterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.
• beclomethasone/salbutamol combination · Respiratory
  Beclomethasone is a corticosteroid that reduces inflammation, while salbutamol is a beta-2 adrenergic receptor agonist that relaxes airway smooth muscle.
• Budesonide 200 µg plus formoterol 6 µg DPI · Respiratory
  Budesonide reduces airway inflammation while formoterol relaxes airway smooth muscle, together improving airflow and reducing asthma/COPD symptoms.
• budesonide plus formoterol combination · Respiratory
  Budesonide is a corticosteroid that reduces inflammation, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes airway muscles.
• CHF 1535 · Respiratory / Pulmonology
  CHF 1535 is a dual bronchodilator that combines a long-acting beta-2 agonist with a long-acting muscarinic antagonist to improve airway function in chronic obstructive pulmonary disease.
• CHF 1535 100/6 µg · Respiratory/Pulmonology
  CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.
• CHF 1535 100/6 NEXT DPI® 2 months · Respiratory/Pulmonology
  CHF 1535 is a fixed-dose combination of beclomethasone dipropionate and formoterol fumarate delivered via a dry powder inhaler for maintenance treatment of asthma and COPD.
• CHF 1535 100/6 pMDI 2 months · Respiratory/Pulmonology
  CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.
• CHF 1535 200/6 µg · Respiratory/Pulmonology
  CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.
• CHF 1535 50/6µg · Respiratory/Pulmonology
  CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.
• CHF 5993 100/6/12.5 µg · Respiratory/Pulmonology
  CHF 5993 is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways.
• CHF 5993 200/6/12.5 µg · Respiratory/Pulmonology
  CHF 5993 is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, long-acting muscarinic antagonist, and inhaled corticosteroid to improve airway function and reduce inflammation in chronic obstructive pulmonary disease.
• CHF1535 200/6 µg pMDI · Respiratory/Pulmonology
  CHF1535 is a fixed-dose combination of beclomethasone dipropionate (ICS) and formoterol (LABA) that reduces airway inflammation and improves bronchial smooth muscle relaxation.
• FlF/VI + Tiotropium · Respiratory/Pulmonology
  FlF/VI is a fixed-dose combination of fluticasone furoate and vilanterol (long-acting beta-2 agonist and inhaled corticosteroid) combined with tiotropium (long-acting muscarinic antagonist) to provide multi-mechanism bronchodilation and anti-inflammatory effects in chronic obstructive pulmonary disease.
• Fluticasone plus salmeterol fixed combination · Respiratory/Pulmonology
  Fluticasone (a corticosteroid) reduces airway inflammation while salmeterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.
• Formoterol 12 µg DPI · Respiratory
  Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
• Formoterol powder 12 µg/unit dose · Respiratory
  Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow.
• Foster® NEXThaler® 100/6 µg/unit dose · Respiratory/Pulmonology
  Foster NEXThaler combines beclomethasone dipropionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma and COPD.
• Oleogel-S10 · Dermatology / Wound Care
  Oleogel-S10 is a topical oleogel formulation containing birch bark extract that promotes wound healing and tissue repair through anti-inflammatory and antimicrobial properties.
• Seretide® Accuhaler® 250/50 µg/actuation · Respiratory / Pulmonology
  Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.
• Seretide Accuhaler® 500/50 µg/actuation · Respiratory
  Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.
• tobramycin / Bramitob
• tobramycin / TOBI

Phase 2 pipeline

• BDP DPI and formoterol DPI · Respiratory/Pulmonology
  This combination inhaler delivers beclomethasone dipropionate (a corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in obstructive airway diseases.
• Budesonide extrafine pMDI · Respiratory
  Budesonide extrafine pMDI is a corticosteroid that works by reducing inflammation in the lungs.
• CHF 1531 pMDI
• CHF 1535 Next DPI · Respiratory
  CHF 1535 Next DPI is a dry powder inhaler for the treatment of cystic fibrosis.
• CHF 1535 pMDI
• CHF 4226 pMDI · Respiratory
  CHF 4226 is an inhaled dual bronchodilator combining a long-acting beta-2 agonist and long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.
• CHF 5188 pMDI
• CHF 5259 · Cardiovascular
  CHF 5259 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.
• CHF 5259 12.5 µg
• CHF 5993 DPI · Respiratory
  CHF 5993 DPI is a dry powder inhaler formulation of a specific drug.
• CHF 6001 Dose1
• CHF 718 pMDI · Respiratory
  CHF 718 pMDI is a corticosteroid used to reduce inflammation in the airways.
• CHF1535 daily dose
• CHF1535 NEXT DPI · Respiratory/Pulmonology
  CHF1535 is a dual bronchodilator combining an inhaled corticosteroid with a long-acting beta-2 agonist and long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.
• CHF1535 NEXThaler · Respiratory
  CHF1535 NEXThaler is a dry powder inhaler delivering a fixed dose of a combination of fluticasone furoate and umeclidinium
• CHF1535 pMDI · Respiratory
  CHF1535 pMDI is a corticosteroid inhalation powder.
• CHF5633 · Respiratory
  CHF5633 is a small molecule in development for the treatment of cystic fibrosis.
• CHF5993 pMDI · Respiratory
  CHF5993 pMDI is a corticosteroid inhalation powder for the maintenance treatment of asthma and the treatment of chronic obstructive pulmonary disease (COPD).
• CHF5993 pMDI with HFA-134a · Respiratory
  CHF5993 pMDI with HFA-134a is a pressurized metered-dose inhaler formulation of a corticosteroid.
• CHF5993 pMDI with HFA-152a
• CHF6001
• CHF6001 DPI · Respiratory
  CHF6001 DPI is a dry powder inhaler formulation of a long-acting muscarinic antagonist.
• CHF718 pMDI with HFA-134a
• Clenil® Modulite® via AeroChamber Plus™ · Respiratory
  Clenil Modulite is a corticosteroid that reduces inflammation in the airways.
• Clenil® Modulite® via Volumatic™ spacer

Phase 1 pipeline

• CH6001
• CHF 5993 pMDI
• CHF 6333
• CHF5259
• CHF5259 and CHF6001
• CHF6333
• CHF6366
• CHF6467 active
• CHF6523
• Cimetidine plus CHF5993 pMDI
• pMDI standard actuator
• Supra-therapeutic Dose
• Therapeutic Dose 1

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Chiesi Farmaceutici S.p.A. portfolio CI brief
• Chiesi Farmaceutici S.p.A. pipeline updates RSS

Frequently asked questions about Chiesi Farmaceutici S.p.A.

Related

• Atimos® · Respiratory / Pulmonology
• Beclometasone/Formoterol · Respiratory/Pulmonology
• CHF1535 · Respiratory/Pulmonology
• CHF5993 · Other
• elapegademase-lvlr
• Sector hub: All tracked pharma companies